Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174733 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT00174733 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 456 participants.
The verdict
NCT00174733, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
Interventions
- DRUG Ciclesonide (XRP1526)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174733
The ClinicalTrials.gov registry entry for NCT00174733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ciclesonide (XRP1526) is the first listed.
NCT00174733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174733 about?
NCT00174733 is a clinical study titled "Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid". To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
What is the current status of trial NCT00174733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2005-07. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00174733?
The interventions under investigation include: Ciclesonide (XRP1526) (DRUG).
Who is sponsoring clinical trial NCT00174733?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.